Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898557392> ?p ?o ?g. }
- W2898557392 endingPage "9" @default.
- W2898557392 startingPage "1" @default.
- W2898557392 abstract "Introduction: Type 2 diabetes mellitus is characterized by increased cardiovascular morbidity and mortality. Atherogenic dyslipidemia is common in this population, consisting of the triad of increased triglycerides, increased small dense low-density lipoprotein (LDL) particles and decreased high-density lipoprotein cholesterol (HDL-C) levels, leading to increased cardiovascular risk.Areas covered: Aim of the review is the presentation of pharmacokinetic characteristics of the currently available sodium-glucose cotransporters 2 (SGLT-2) inhibitors and the effects of these drugs on lipid metabolism. SGLT-2 inhibitors share a common favorable pharmacokinetic profile, are orally administered with long half-lives (allowing for a once daily dosing) and have been proven to be effective in reducing blood glucose levels. However, the SGLT-1 inhibitory capacity differs between these drugs, an effect that may affect their antidiabetic and cardiovascular effects. SGLT-2 inhibitors alter serum lipids modestly in a similar manner. Specifically, an increase of total cholesterol, LDL cholesterol, and HDL-C levels as well as a decrease of triglycerides concentration is observed. Additionally, the administration of these agents may reduce the atherogenic small dense LDL particle levels, an effect that could provide additional cardiovascular protection in the long term.Expert opinion: The effect of SGLT-2 inhibitors on diabetic dyslipidemia may be one of their cardioprotective mechanisms." @default.
- W2898557392 created "2018-11-02" @default.
- W2898557392 creator A5014316552 @default.
- W2898557392 creator A5024798909 @default.
- W2898557392 creator A5032218366 @default.
- W2898557392 creator A5046306526 @default.
- W2898557392 creator A5056379080 @default.
- W2898557392 date "2018-10-25" @default.
- W2898557392 modified "2023-09-29" @default.
- W2898557392 title "SGLT-2 inhibitors: pharmacokinetics characteristics and effects on lipids" @default.
- W2898557392 cites W1955804425 @default.
- W2898557392 cites W1967357406 @default.
- W2898557392 cites W1996760589 @default.
- W2898557392 cites W2000820541 @default.
- W2898557392 cites W2010055261 @default.
- W2898557392 cites W2031730303 @default.
- W2898557392 cites W2038126428 @default.
- W2898557392 cites W2038967042 @default.
- W2898557392 cites W2046814073 @default.
- W2898557392 cites W2057676273 @default.
- W2898557392 cites W2091885991 @default.
- W2898557392 cites W2097089354 @default.
- W2898557392 cites W2099111050 @default.
- W2898557392 cites W2104005551 @default.
- W2898557392 cites W2106285042 @default.
- W2898557392 cites W2107952252 @default.
- W2898557392 cites W2122996236 @default.
- W2898557392 cites W2124872768 @default.
- W2898557392 cites W2126194898 @default.
- W2898557392 cites W2127307547 @default.
- W2898557392 cites W2127826926 @default.
- W2898557392 cites W2144295528 @default.
- W2898557392 cites W2145444246 @default.
- W2898557392 cites W2146264128 @default.
- W2898557392 cites W2148328779 @default.
- W2898557392 cites W2164324917 @default.
- W2898557392 cites W2166613497 @default.
- W2898557392 cites W2170888045 @default.
- W2898557392 cites W2171183320 @default.
- W2898557392 cites W2173615285 @default.
- W2898557392 cites W2328718696 @default.
- W2898557392 cites W2442475309 @default.
- W2898557392 cites W2468433183 @default.
- W2898557392 cites W2515456868 @default.
- W2898557392 cites W2531285001 @default.
- W2898557392 cites W2537155629 @default.
- W2898557392 cites W2547375753 @default.
- W2898557392 cites W2550194700 @default.
- W2898557392 cites W2551644574 @default.
- W2898557392 cites W2552966671 @default.
- W2898557392 cites W2562899840 @default.
- W2898557392 cites W2563118716 @default.
- W2898557392 cites W2576291926 @default.
- W2898557392 cites W2581291007 @default.
- W2898557392 cites W2587032970 @default.
- W2898557392 cites W2590820596 @default.
- W2898557392 cites W2595706111 @default.
- W2898557392 cites W2603386412 @default.
- W2898557392 cites W2604205657 @default.
- W2898557392 cites W2626446274 @default.
- W2898557392 cites W2731777658 @default.
- W2898557392 cites W2761312904 @default.
- W2898557392 cites W2766117987 @default.
- W2898557392 cites W2770478746 @default.
- W2898557392 cites W2774613779 @default.
- W2898557392 cites W2783816371 @default.
- W2898557392 cites W2786474120 @default.
- W2898557392 cites W2795064071 @default.
- W2898557392 cites W2797046378 @default.
- W2898557392 cites W2807608863 @default.
- W2898557392 cites W2809312083 @default.
- W2898557392 cites W4250332773 @default.
- W2898557392 doi "https://doi.org/10.1080/17425255.2018.1541348" @default.
- W2898557392 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30360662" @default.
- W2898557392 hasPublicationYear "2018" @default.
- W2898557392 type Work @default.
- W2898557392 sameAs 2898557392 @default.
- W2898557392 citedByCount "21" @default.
- W2898557392 countsByYear W28985573922019 @default.
- W2898557392 countsByYear W28985573922020 @default.
- W2898557392 countsByYear W28985573922021 @default.
- W2898557392 countsByYear W28985573922022 @default.
- W2898557392 countsByYear W28985573922023 @default.
- W2898557392 crossrefType "journal-article" @default.
- W2898557392 hasAuthorship W2898557392A5014316552 @default.
- W2898557392 hasAuthorship W2898557392A5024798909 @default.
- W2898557392 hasAuthorship W2898557392A5032218366 @default.
- W2898557392 hasAuthorship W2898557392A5046306526 @default.
- W2898557392 hasAuthorship W2898557392A5056379080 @default.
- W2898557392 hasConcept C112705442 @default.
- W2898557392 hasConcept C126322002 @default.
- W2898557392 hasConcept C134018914 @default.
- W2898557392 hasConcept C2778096610 @default.
- W2898557392 hasConcept C2778163477 @default.
- W2898557392 hasConcept C2908647359 @default.
- W2898557392 hasConcept C555293320 @default.
- W2898557392 hasConcept C71924100 @default.
- W2898557392 hasConcept C98274493 @default.